WO2023239684A1 - Methodology related to dehydration treatment - Google Patents
Methodology related to dehydration treatment Download PDFInfo
- Publication number
- WO2023239684A1 WO2023239684A1 PCT/US2023/024513 US2023024513W WO2023239684A1 WO 2023239684 A1 WO2023239684 A1 WO 2023239684A1 US 2023024513 W US2023024513 W US 2023024513W WO 2023239684 A1 WO2023239684 A1 WO 2023239684A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- module
- oral fluid
- serving
- administered
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 78
- 238000011282 treatment Methods 0.000 title claims abstract description 27
- 208000005156 Dehydration Diseases 0.000 title description 14
- 230000018044 dehydration Effects 0.000 title description 13
- 238000006297 dehydration reaction Methods 0.000 title description 13
- 239000012530 fluid Substances 0.000 claims abstract description 100
- 230000001154 acute effect Effects 0.000 claims abstract description 18
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 14
- 230000036571 hydration Effects 0.000 claims description 49
- 238000006703 hydration reaction Methods 0.000 claims description 49
- 230000006872 improvement Effects 0.000 claims description 26
- 235000005911 diet Nutrition 0.000 claims description 7
- 230000037213 diet Effects 0.000 claims description 7
- 239000008151 electrolyte solution Substances 0.000 claims description 6
- 230000037081 physical activity Effects 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 238000003287 bathing Methods 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000004243 sweat Anatomy 0.000 claims description 3
- 238000011084 recovery Methods 0.000 description 26
- 239000003792 electrolyte Substances 0.000 description 16
- 150000001720 carbohydrates Chemical class 0.000 description 10
- 235000014633 carbohydrates Nutrition 0.000 description 10
- 206010057190 Respiratory tract infections Diseases 0.000 description 9
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 206010037660 Pyrexia Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000000741 diarrhetic effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 208000019206 urinary tract infection Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940021013 electrolyte solution Drugs 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010014418 Electrolyte imbalance Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 235000003332 Ilex aquifolium Nutrition 0.000 description 3
- 241000209027 Ilex aquifolium Species 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000004630 mental health Effects 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 239000000310 rehydration solution Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- 206010012310 Dengue fever Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000000876 binomial test Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000013523 data management Methods 0.000 description 2
- 208000025729 dengue disease Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000002864 food coloring agent Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000276 sedentary effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000025599 Heat Stress disease Diseases 0.000 description 1
- 206010019330 Heat cramps Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000034782 Lid sulcus deepened Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000008284 inappropriate ADH syndrome Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000005960 long-lasting response Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000007960 nature-identical flavoring substance Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000013031 physical testing Methods 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/56—Flavouring or bittering agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/58—Colouring agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/62—Clouding agents; Agents to improve the cloud-stability
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/68—Acidifying substances
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0278—Product appraisal
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0282—Rating or review of business operators or products
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Social work or social welfare, e.g. community support activities or counselling services
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
Definitions
- Body fluids are present in different body compartments and contain minerals, salts, dissolved proteins, fatty acids, glucose etc.
- the human body contains about 60% of water as body fluid, which is vital for life and performs or helps facilitate various functions like the transport of oxygen and nutrients in the body, temperature regulation, maintenance of internal environment, etc.
- Electrolytes in the body are essential minerals that carry an electrical charge. They are important constituents of human body fluids and help in regulating various physiological body functions.
- Fluid and electrolyte imbalance in the body can result from decreased intake of fluids and/or increased fluid loss from the body in adverse conditions. Electrolyte imbalances may result from an increase or decrease concentration of sodium, potassium, calcium, and magnesium in the body.
- Some of the common causes of fluid and electrolyte imbalance in the body are viral illnesses, fever due to any cause, heat-related illnesses and gastrointestinal (GT) related conditions (nausea, vomiting, diarrhea, etc.).
- GT gastrointestinal
- Such fluid and electrolyte imbalance in the body may lead to “dehydration,” which may be defined as a harmful reduction in the amount of water in the body.
- Dehydration is often due to increased output because of diarrhea and vomiting in gastroenteritis and is recognized easily and treatment provided as per guidelines.
- Symptoms of dehydration in an infant or young child may include dry mouth and tongue, no tears when crying, no wet diapers for three hours, sunken eyes and/or cheeks, sunken soft spot on top of skull, and listlcssncss and/or irritability.
- Symptoms of dehydration in an adult may include extreme thirst, less frequent urination, dark-colored urine, fatigue, dizziness and/or confusion.
- a further objective of the present invention is to provide a method to evaluate the effectiveness of oral fluid along with a standard of care medication treatment to help restore body fluid (hydration) and/or energy in subjects with acute common non-diarrheal illnesses with fever and/or general weakness, e.g., such as upper respiratory tract infection.
- An objective of the present invention is to provide a method to evaluate the effectiveness of oral fluid in a naturalistic environment, for example at home, i.e. that does not need to be in a medical environment.
- Another objective of the present invention is to provide a method to evaluate the effectiveness of oral fluid without having to screen the subjects for mental or physical conditions.
- Another objective of the present invention is to provide a method to evaluate the effectiveness of oral fluid in addition to standard care.
- An objective is to provide a method to evaluate the effectiveness of oral fluid without having to change the subject’s diet and fluid intake.
- a first embodiment of the invention relates to method to assess an effectiveness of an oral fluid in a treatment of a subject suffering from an acute non-diarrhea illness, the method including: a) having the subject answer a self-rating questionnaire comprising a module related to hydration level, where the subject selects a self-rating based on a 1 to 5 scale to create a baseline value; b) administering a first serving of the oral fluid to the subject; c) having the subject repeat the self-rating questionnaire at least one time over a 72-hour period after the first serving of the oral fluid is administered to create at least one additional value; and d) measuring a variation between the at least one additional value collected in step c) and the baseline value collected in step a), where the variation indicates the effectiveness of the oral fluid in the treatment of the subject.
- a second embodiment of the invention relates to a method to assess an effectiveness of an oral fluid in a treatment of a subject suffering from an acute non-diarrhea illness, the method including: a) having the subject answer a self-rating questionnaire comprising a first module and a second module, where the first module relates to energy level and the second module relates to hydration level, and where the subject selects a self-rating on a 1 to 5 scale to create a baseline value for each of the first module and the second module; b) administering a first serving of the oral fluid to the subject; c) having the subject repeat the self-rating questionnaire at least one time over a 72-hour period after the first serving of the oral fluid is administered to create at least one additional value for each of the first module and the second module; and d) measuring a variation between the at least one additional value collected in step c) and the baseline value collected in step a) for each of the first module and the second module, wherein the variation indicates the effectiveness of the oral fluid
- the subject may repeat the self-rating questionnaire at least one time during the first 24 hours after the first serving of the oral fluid is administered. According to another embodiment, the subject may repeat the self-rating questionnaire at least one time during a period between 1 hour and 72 hours after the first serving of the oral fluid is administered. According to a further embodiment, the subject may repeat the self-rating questionnaire at least one time during the first 24 hours after the first serving of the oral fluid is administered, and may repeat the self-rating questionnaire at least one additional time during a period between 1 hour and 72 hours after the first serving of the oral fluid is administered.
- the method may further include an additional step of determining from the variation whether the subject experienced an improvement in the module (as described in the first embodiment), or in the first module and/or the second module (as described in the second embodiment).
- the oral fluid may be a ready to drink electrolyte solution.
- the subject does not need to be in a medical environment, such as a hospital, when the method is performed.
- the subject has no limitation on diet during the method, particularly, no limitation on fluid intake after the first serving of the oral fluid is administered.
- the first module may comprise a question asking the subject to rate his/her level of energy and may further comprise examples of normal physical activities such as dressing, toileting, eating, bathing, that the subject should be able to perform when adequately energized.
- the module (as described in the first embodiment) and/or the second module (as described in the second embodiment) may comprise a question asking the patient to rate his/her level of hydration and may further comprise examples such as having moist tongue/mouth, being able to make saliva or spit, being able to sweat, not feeling thirsty, that the patient should be able to experience when adequately hydrated.
- the 1 to 5 scale further may include a description of physical symptoms associated with each value of the 1 to 5 scale.
- the method may be implemented by a software on a mobile device such as a smartphone.
- the software may use the baseline value collected to recommend a type or amount of oral fluid to be administered to the subject.
- the software may further enable the purchase of the type of oral fluid to be administered to the subject.
- the software may use the variation measured to determine whether the subject experienced an improvement in the module or whether additional treatment may be necessary. Further, the software may be used by the subject or a medical professional.
- the method may be adapted to assess an effectiveness of an oral fluid in the treatment of multiple subjects suffering from the same or various acute non-diarrhea illnesses.
- One embodiment of the invention relates to an assessment method of the effectiveness of oral fluid in speed of recovery from acute non-diarrhea illnesses of a subject, the method including: a) submitting a subject to a self-rating questionnaire having at least one module, to create a baseline value; where the module is rated on a 1 to 5 scale and refers to hydration level; b) administering a first serving of an oral fluid to the subject; c) repeating the self-rating questionnaire at least 1 time over a 72 hour period after the first serving of the oral fluid is administered; and d) measuring variation in selfrating collected over the c) step period in comparison to the baseline collected in step a).
- Another embodiment of the invention relates to an assessment method of the effectiveness of oral fluid in speed of recovery from acute non-diarrhea illnesses of a subject, the method including: a) submitting the subject to a self-rating questionnaire having at least one module, to create a baseline value; where the module is rated on a 1 to 5 scale and refers to energy level; b) administering a first serving of an oral fluid to the subject; c) repeating the self-rating questionnaire at least 1 time over a 72 hour period after the first serving of the oral fluid is administered; and d) measuring variation in selfrating collected over the c) step period in comparison to the baseline collected in step a).
- a further embodiment of the invention relates to an assessment method of the effectiveness of oral fluid in speed of recovery from acute non-diarrhea illnesses of a subject, the method including: a) submitting the subject to a self-rating questionnaire having at least 2 modules, to create a baseline value, where each module is rated on a 1 to 5 scale and includes a module referring to energy level and a module referring to hydration level; b) administering a first serving of an oral fluid to the subject; c) repeating self-rating questionnaire at least 1 time over a 72-hour period after the first serving of the oral fluid is administered; and d) measuring variation in self rating collected over the c) step period in comparison to the baseline collected in step a).
- module it is meant one or more questions having a particular aspect of the subject physical condition in common.
- the number of questions in a module is not limited and a module may include one question or more, for example two questions, three questions, four questions; preferably each module includes one question.
- oral fluid any aqueous solution comprising electrolytes and carbohydrates that may be orally ingested by or administered to a subject, such as ready to drink electrolyte solutions.
- Electrolytes maybe selected from sodium, potassium, chlorine, citrates, carbonates, bicarbonates, and combinations thereof.
- Carbohydrates may be glucose or other mono or disaccharides. Electrolytes are beneficial for hydration and carbohydrates are beneficial for energy restoration.
- the oral fluid may contain other elements such as magnesium, calcium; or molecules such as taurine or vitamin, for example vitamin C.
- the said oral fluid is a ready to drink electrolyte solutions.
- the said oral fluid is a fruit-based drink with electrolytes.
- the oral fluid may be administered to a subject in need thereof several times a day, for example 1 to 8 times per day, for example 1 to 6 times per day, for example 1 to 4 times per day, for example 2 to 6 times per day, for example 2 to 4 times per day, for example 3 to 6 times per day, for example 3 to 4 times per day; over a period of 24 hours or 48 hours or 72 hours, or over a period as per medical requirement or as medically prescribed.
- the appropriate number of servings of oral fluid per day, as well as the period over which the servings of the oral fluid should be administrated, to a particular subject is dependent on and defined by the subject’s specific need, based, for example, on medical advice.
- serving of an oral fluid it is meant the volume of oral fluid to be administered to a subject. This volume is subject dependent and is defined as per subject need, based on a medical advice or prescription, given the concentration in electrolytes and carbohydrates of said oral fluid.
- Other hour combinations are also possible, including, for example, any combination of 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 56 and 72 hours after the first serving of the oral fluid has been administered.
- Assessments made within the first hour after the first serving of the oral fluid is administered provide information about the onset of response to treatment with the oral fluid, for example the instant energy recovery or the hydration recovery.
- Assessments made between the first hour and 72 hours after the first serving of the oral fluid first serving administration provide information about the long-lasting response to treatment with the oral fluid, for example the energy recovery or the hydration recovery.
- Examples of “acute non-diarrhea illnesses” may include for example subjects with symptoms such as fever, general weakness, nausea, vomiting; and subjects with conditions like viral illnesses, heat related illness, upper respiratory tract infection (URTI) and urinary tract infections (UTI).
- URTI upper respiratory tract infection
- UTI urinary tract infections
- the assessment method may comprise an additional step e) after step d) where step e) is: determining from the measure of step d) the percentage of subject experiencing improvement in one of the energy level module or the hydration level module.
- step e) is: determining from the measure of step d) the percentage of subject experiencing improvement in one of the energy level module or the hydration level module.
- experience an “improvement” in a module it is meant at least a 1 -point increase in rating, compared to the baseline obtained in step a).
- the assessment method may comprise an alternative additional step e’) after step d) where step e’) is: determining from the measure of step d) the percentage of subject experiencing improvement in both the energy level module and the hydration level module.
- the assessment method may comprise an alternative additional step e”) after step d) where step e”) is: determining from the measure of step d) the percentage of subject experiencing improvement in the hydration level module.
- the assessment method may exclude questions related to mental health when screening the subject. Eliminating the need to screen subjects for mental health allows the methodology to be simplified for home environment use or any other use that does not require medical supervision.
- Mental health screening questions for example those related to depression, are routinely included in medical patient health screening questionnaires.
- the assessment method may also exclude the requirement of any physical test to be performed to screen the subject. Eliminating the requirement for a subject’s physical or medical testing (e.g., urine sample and/or blood work) allows the methodology to be simplified for home environment use or any other use that does not require medical supervision. Furthermore, some physical tests for subjects or patients (e.g., urine color) may be misleading and direct the wrong diagnosis. For example, urine color is darker or lighter depending on the subject and, therefore, is not a reliable indicator of dehydration.
- physical or medical testing e.g., urine sample and/or blood work
- urine color may be misleading and direct the wrong diagnosis. For example, urine color is darker or lighter depending on the subject and, therefore, is not a reliable indicator of dehydration.
- the assessment method may not need the subject to be in a medical environment, such as a hospital, when the method is performed. It may be beneficial to be able to perform this assessment outside of a medical environment because it allows a subject to evaluate the effectiveness of the oral fluid in naturalistic condition (real life condition) when the subject is at home (in the home environment) or in a remote location. In other words, being able to perform this assessment without any medical environment enables naturalistic, or “in the home environment”, evaluation of the oral fluid without the need of any particular instrument or medical setup. It simplifies the assessment and makes it easier for the subject to comply with the assessment method.
- the assessment method may not need any limitation on the subject’s diet during the method implementation, particularly, no limitation on fluid intake after the first serving of an oral fluid administration of step b). Allowing the subject to keep their regular diet and hydration pattern may be beneficial because it allows naturalistic evaluation of the effectiveness of oral fluid administered. It further provides evidence that the improvement in the subject hydration or energy, or both energy and hydration, is not related to a change in the subject’ s regular diet and hydration pattern but indeed due to the absorption of the oral fluid. Finally, it does not introduce any burden on the subject in their daily routine, such as the subject’s natural diet and hydration pattern.
- the energy level module may include a question asking the subject to rate his/her level of energy and may provide examples of normal physical activities such as dressing, toileting, eating, bathing, that the subject should be able to perform. Examples like this may help the subject to understand what to focus on.
- the energy level module may also include other examples of normal physical activities, in addition to or instead of those listed above.
- the rating and/or question may focus on examples of abnormal physical activities such as fatigue and weakness.
- the hydration level module may include a question asking the subject to rate his/her level of hydration and may provide examples such as having moist tongue/mouth, being able to make saliva or spit, being able to sweat, not feeling thirsty; that the subject should be able to experience when adequately hydrated. Examples like this may help the subject to understand what to focus on.
- the hydration level module may also include other examples of feeling adequately hydrated, in addition to or instead of those listed above.
- the rating and/or question may focus on examples of dehydration such as thirst and dry mouth.
- the 1 to 5 scale in the module of the self-rating questionnaire may be associated with indications of which value is the worst and which is the best.
- This indication or a similar indication may enable the subject to avoid any mistake when assessing the effectiveness of the oral fluid.
- Different subjects, based on their own subjective perception, may consider either 1 or 5 as associated with the best experience. Misinterpretation of the ranking scale may result in subjects providing ranking opposite to their intent. Giving a clear indication of the ranking scale end points relative value helps to avoid any confusion.
- the 1 to 5 scale in the module of the self-rating questionnaire may be associated with a description of physical symptoms for at least part of the values of the scale.
- This indication or a similar indication may enable the subject to avoid any mistake when assessing the effectiveness of the oral fluid.
- Different subjects, based on their own subjective perception, may consider cither 1 or 5 as associated with the best experience. Misinterpretation of the ranking scale may result in subjects providing ranking opposite to their intent. Giving a clear indication of the ranking scale end points relative value helps to avoid any confusion.
- the assessment method may be implemented by software or a software App on a mobile device such as a smartphone.
- a smartphone may make it easier to use and/or more convenient for the subject and/or medical professional using the App. It would allow the assessment method to be used outside medical facilities and/or the home environment. Having data directly in a digital format also allows reduction of paperwork and potential transcription mistakes.
- the assessment method may be implemented by a software App on a mobile device, where the App may be programmed to make a recommendation for the purchase of oral fluid, such as a ready to drink electrolyte solutions or fruit-based drink with electrolytes.
- the recommendation may be made by an algorithm that evaluates the subject’s answers to the self-rating questionnaire.
- the recommendation could also be made by a medical professional that is affiliated with the App, for example a virtual doctor or nurse.
- the software App may be further able to link a recommendation to a third-party website selling the recommended oral fluid or may have a direct-to-consumer purchase platform for the recommended oral fluid, so that the subject can immediately purchase the oral fluid for treatment.
- Having an automatic recommendation of an appropriate oral fluid with electrolytes and carbohydrates, such as a ready to drink electrolyte solution may help the subject to get quick access to the relevant product to address the lack of hydration and/or energy.
- the App were used by a medical professional, rather than by the subject or patient, it may also help the medical staff to make recommendation of products adapted to the subject needs.
- Study Design To study the effect of oral fluid in dehydration and energy recovery in subjects, using the above referenced assessment methodology the following prospective, interventional, open-label, multicenter, naturalistic study involving subjects was conducted. Subjects were supplied with an oral fluid, in particular with one of the ORSL® variants (ORSL® Apple Drink or ORSL® PLUS Orange Drink), as an adjuvant along with standard of care medication treatment, as per physician’ s discretion in subjects experiencing acute common non-diarrheal illnesses with fever and/or general weakness, e.g. upper respiratory tract infection (URTI).
- ORSL® variants ORSL® Apple Drink or ORSL® PLUS Orange Drink
- Study Population Patient inclusion criteria included subjects greater or equal to 18 years of age, who:
- Subjects with pre-existing medical conditions that may have impacted study measurements or ability to comply with study procedures including but not limited to malabsorption syndrome, congestive heart failure, cirrhosis, hepatic failure, malignancy, sepsis, chronic infections like Tuberculosis, Chronic obstructive pulmonary disease, Syndrome of inappropriate antidiuretic hormone secretion, renal failure, etc.
- Discontinuation Criteria Subjects who developed diarrhea, or were diagnosed with malaria, culturepositive typhoid, dengue, CO VID-19 (newly diagnosed), etc. or required hospitalisation for any cause were discontinued from the study. However, data collected for such subjects were retained for the purpose of analysis and no further efforts were made to obtain or record additional information regarding the subject from the point of discontinuation.
- Data Collection/Data Sources The data for the study was collected at relevant data timepoints as presented in the data collection schedule. At baseline, the treating physician carried out a physical examination and recorded demographics, medical history, details of primary ailment) s) and the standard of care medication treatment and their concomitant medications (including nutritional supplements). The data for effectiveness evaluation was recorded by subjects on PRO questionnaires in the home environment. Physicians recorded the 72-hour evaluation on the Physician Recommendation experience questionnaire. For safety evaluation, adverse event (AEs) and serious adverse events (SAEs) were recorded starting from the time of signing of the ICF. The staff from individual sites entered the study data in the electronic case report forms (eCRFs) of the Electronic data capture (EDC) system.
- ECC Electronic data capture
- the CRFs included programming checks to obtain immediate feedback if data were missing, out of range, illogical or potentially erroneous. Concurrent manual data review was performed based on parameters dictated by the data management plan.
- the truncated Holm multiple comparison procedure (a hybrid of its conventional form and the Bonferroni method) with a truncation fraction, 1/2, was applied.
- the three primary endpoints (at 6 hours, 24 hours and 48 hours) were categorized into the primary family, and the other 3 timepoints (at 20 mins, 40 mins and 60 mins) were categorized into the secondary family.
- End of Study Definition The study was conducted over a period of 72 hours for each subject (and up to 78 hours in case follow-up of an AE was required).
- ORSL® Apple Drink is a fruit juice -based drink with electrolytes (sodium, potassium and chloride), vitamin C and carbohydrates in a 200 mL pack. It is presented in a tetrabrik aseptic package.
- ORSL® PLUS Orange Drink is a fruit juice-based drink with electrolytes (sodium, potassium and chloride), vitamin C and carbohydrates in a 200 mL pack. It is presented in a tetrabrik aseptic package.
- ORSL® Apple Drink and ORSL® PLUS Orange Drink are Food products classified as “Electrolyte Drink”, not ORS, under applicable regulations laid down by Food Standard and Safety Authority of India. Exemplary ingredient and nutritional information of the ORSL® Apple Drink and ORSL® PLUS Orange Drink are provided below:
- ORSL® Apple Drink ( Figure 1):
- Aided Recovery Scale Questionnaire consisted of 2 questions i.e., “Rate your level of energy” and “Rate your level of hydration”, which corresponded to 2 primary objectives of the study. Subjects provided their response to these questions on a scale from 1 to 5 after self-assessment of their condition of illness and how much they feel recovered after taking ORSL® variant. The responses were as follows: Strongly Disagree-1 to Strongly Agree-5. Further details on these 2 questions are provided in table below.
- An exemplary Aided Recovery Scale Questionnaire may be as follows:
- Aided Recovery Scale questionnaire comprises two modules, one relating to energy: “Rate your level of energy”; and one related to hydration: “Rate your level of hydration”. Both provide examples of physical activities that the patient should be able to perform or experience when having an adequate level of energy or being adequately hydrated. These examples are provided to help the patient in the self-rating.
- Screening Subjects were included in the study and were screened for inclusion and exclusion criteria after they or their legal representative agreed to participate in the study and signed the ICF. The subjects meeting all the eligibility criteria were enrolled in the study. The enrolled subject’s baseline data was collected by the treating physician (or designee) before administering first usage of any of the ORSL® variants.
- Results 617 subjects were enrolled in the study. 310 subjects received the ORSL Apple variant, and 307 subjects received the ORSL Orange Variant. All subjects completed the study, no discontinuation was observed. 62.4% of subjects were male and 37.6% of the subjects were female. The median age was 36 years (minimum 18 years, maximum 79 years). The mean age was 38.3 years with a standard deviation of 12.85. The baseline BMI (kg/m 2 ) had a mean value of 23.85 (Std Dev 3.127), and a median value of 23.60.
- Table 2 shows the percentage of subject feeling an improvement in energy on “Aided Recovery Scale” after 6, 24 and 48hours of ORSL® variants consumption. By “improvement” is meant at least 1 point improvement from baseline.
- Percentage improved was statistically significantly greater than 50%.
- the truncated Holm multiple comparison procedure was applied in order to strongly control the family wise Type I error rate at 0.025, one-sided.
- the assessment methodology demonstrates the ability to detect low levels of hydration and/or energy and assess improvement in hydration and energy levels in subjects over time after administration of oral fluids.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Business, Economics & Management (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Strategic Management (AREA)
- Finance (AREA)
- Accounting & Taxation (AREA)
- Primary Health Care (AREA)
- Development Economics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Economics (AREA)
- Medical Informatics (AREA)
- Marketing (AREA)
- Public Health (AREA)
- Theoretical Computer Science (AREA)
- General Business, Economics & Management (AREA)
- Entrepreneurship & Innovation (AREA)
- Tourism & Hospitality (AREA)
- Game Theory and Decision Science (AREA)
- Child & Adolescent Psychology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Human Resources & Organizations (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A method to assess the effectiveness of an oral fluid in the treatment of a subject suffering from an acute non-diarrhea illness, the method including: having the subject answer a self-rating questionnaire, where the subject selects a self-rating based on a 1 to 5 scale to create a baseline value; administering a first serving of the oral fluid to the subject; having the subject repeat the self-rating questionnaire at least one time over a 72-hour period after the first serving of the oral fluid is administered to create at least one additional value; and measuring a variation between the at least one additional value and the baseline value, where the variation indicates the effectiveness of the oral fluid in the treatment of the subject.
Description
METHODOLOGY RELATED TO DEHYDRATION TREATMENT
[0001] Body fluids are present in different body compartments and contain minerals, salts, dissolved proteins, fatty acids, glucose etc. The human body contains about 60% of water as body fluid, which is vital for life and performs or helps facilitate various functions like the transport of oxygen and nutrients in the body, temperature regulation, maintenance of internal environment, etc. Electrolytes in the body are essential minerals that carry an electrical charge. They are important constituents of human body fluids and help in regulating various physiological body functions.
[0002] Fluid and electrolyte imbalance in the body can result from decreased intake of fluids and/or increased fluid loss from the body in adverse conditions. Electrolyte imbalances may result from an increase or decrease concentration of sodium, potassium, calcium, and magnesium in the body. Some of the common causes of fluid and electrolyte imbalance in the body are viral illnesses, fever due to any cause, heat-related illnesses and gastrointestinal (GT) related conditions (nausea, vomiting, diarrhea, etc.). Thus, fluid and electrolyte replenishment is an essential component of the care for patients with such acute illnesses.
[0003] Such fluid and electrolyte imbalance in the body may lead to “dehydration,” which may be defined as a harmful reduction in the amount of water in the body. Dehydration is often due to increased output because of diarrhea and vomiting in gastroenteritis and is recognized easily and treatment provided as per guidelines. Symptoms of dehydration in an infant or young child may include dry mouth and tongue, no tears when crying, no wet diapers for three hours, sunken eyes and/or cheeks, sunken soft spot on top of skull, and listlcssncss and/or irritability. Symptoms of dehydration in an adult may include extreme thirst, less frequent urination, dark-colored urine, fatigue, dizziness and/or confusion. In severe cases, dehydration can lead to serious complications like, for example, heat injury (ranging from mild heat cramps to heatstroke), urinary and kidney problems (including urinary tract infections (UTI’s), kidney stones or kidney failure), seizures and/or low blood volume shock (hypovolemic shock).
[0004] While severe cases of dehydration are generally easy to detect, dehydration in acute common non- diarrheal illnesses often remains unnoticed or undiagnosed. These patients may present to their clinicians with a common complaint of general weakness, which may, in fact, be due to reduced intake and / or increased losses of water (e.g., likely due to decrease in appetite or increased insensible losses). [0005] The only effective treatment for dehydration is to replace lost fluids and electrolytes. Water, over- the-counter oral rehydration solutions, sports drinks containing electrolytes, carbohydrate solutions, and intravenous saline solutions are examples of available treatments. There is, however, little clarity on how the management of oral fluid and electrolytes imbalance along with appropriate energy intake (i.e., caloric supply) impacts patient outcome primarily on speed of recovery from acute common non-
diarrheal illnesses, for e.g., patients with fever, general weakness, nausea vomiting and conditions like viral illnesses, heat related illness, upper respiratory tract infection (URTI) etc.
[0006] An objective of the present invention is to provide a method to evaluate the effectiveness of oral fluid for the restoration of hydration and energy level over time. Another objective of the present invention is to provide a method to evaluate the effectiveness of oral fluid for the restoration of hydration or energy level over time.
[0007] A further objective of the present invention is to provide a method to evaluate the effectiveness of oral fluid along with a standard of care medication treatment to help restore body fluid (hydration) and/or energy in subjects with acute common non-diarrheal illnesses with fever and/or general weakness, e.g., such as upper respiratory tract infection.
[0008] An objective of the present invention is to provide a method to evaluate the effectiveness of oral fluid in a naturalistic environment, for example at home, i.e. that does not need to be in a medical environment. Another objective of the present invention is to provide a method to evaluate the effectiveness of oral fluid without having to screen the subjects for mental or physical conditions.
[0009] Another objective of the present invention is to provide a method to evaluate the effectiveness of oral fluid in addition to standard care. An objective is to provide a method to evaluate the effectiveness of oral fluid without having to change the subject’s diet and fluid intake.
Summary of the Invention
[0010] A first embodiment of the invention relates to method to assess an effectiveness of an oral fluid in a treatment of a subject suffering from an acute non-diarrhea illness, the method including: a) having the subject answer a self-rating questionnaire comprising a module related to hydration level, where the subject selects a self-rating based on a 1 to 5 scale to create a baseline value; b) administering a first serving of the oral fluid to the subject; c) having the subject repeat the self-rating questionnaire at least one time over a 72-hour period after the first serving of the oral fluid is administered to create at least one additional value; and d) measuring a variation between the at least one additional value collected in step c) and the baseline value collected in step a), where the variation indicates the effectiveness of the oral fluid in the treatment of the subject.
[0011] A second embodiment of the invention relates to a method to assess an effectiveness of an oral fluid in a treatment of a subject suffering from an acute non-diarrhea illness, the method including: a) having the subject answer a self-rating questionnaire comprising a first module and a second module, where the first module relates to energy level and the second module relates to hydration level, and where the subject selects a self-rating on a 1 to 5 scale to create a baseline value for each of the first module and the second module; b) administering a first serving of the oral fluid to the subject; c) having the subject repeat the self-rating questionnaire at least one time over a 72-hour period after the first serving of the oral fluid is administered to create at least one additional value for each of the first
module and the second module; and d) measuring a variation between the at least one additional value collected in step c) and the baseline value collected in step a) for each of the first module and the second module, wherein the variation indicates the effectiveness of the oral fluid in the treatment of the subject.
[0012] According to an embodiment, the subject may repeat the self-rating questionnaire at least one time during the first 24 hours after the first serving of the oral fluid is administered. According to another embodiment, the subject may repeat the self-rating questionnaire at least one time during a period between 1 hour and 72 hours after the first serving of the oral fluid is administered. According to a further embodiment, the subject may repeat the self-rating questionnaire at least one time during the first 24 hours after the first serving of the oral fluid is administered, and may repeat the self-rating questionnaire at least one additional time during a period between 1 hour and 72 hours after the first serving of the oral fluid is administered.
[0013] According to an embodiment, the method may further include an additional step of determining from the variation whether the subject experienced an improvement in the module (as described in the first embodiment), or in the first module and/or the second module (as described in the second embodiment).
[0014] According to an embodiment, the oral fluid may be a ready to drink electrolyte solution. According to another embodiment, the subject does not need to be in a medical environment, such as a hospital, when the method is performed. According to further embodiment, the subject has no limitation on diet during the method, particularly, no limitation on fluid intake after the first serving of the oral fluid is administered.
[0015] According to an embodiment, the first module may comprise a question asking the subject to rate his/her level of energy and may further comprise examples of normal physical activities such as dressing, toileting, eating, bathing, that the subject should be able to perform when adequately energized.
[0016] According to another embodiment, the module (as described in the first embodiment) and/or the second module (as described in the second embodiment) may comprise a question asking the patient to rate his/her level of hydration and may further comprise examples such as having moist tongue/mouth, being able to make saliva or spit, being able to sweat, not feeling thirsty, that the patient should be able to experience when adequately hydrated.
[0017] According to an embodiment, the 1 to 5 scale further may include a description of physical symptoms associated with each value of the 1 to 5 scale.
[0018] According to a further embodiment, the method may be implemented by a software on a mobile device such as a smartphone. For example, the software may use the baseline value collected to recommend a type or amount of oral fluid to be administered to the subject. The software may further enable the purchase of the type of oral fluid to be administered to the subject. Additionally, the software may use the variation measured to determine whether the subject experienced an improvement in the
module or whether additional treatment may be necessary. Further, the software may be used by the subject or a medical professional.
[0019] According to another embodiment, the method may be adapted to assess an effectiveness of an oral fluid in the treatment of multiple subjects suffering from the same or various acute non-diarrhea illnesses.
Detailed Description
[0020] One embodiment of the invention relates to an assessment method of the effectiveness of oral fluid in speed of recovery from acute non-diarrhea illnesses of a subject, the method including: a) submitting a subject to a self-rating questionnaire having at least one module, to create a baseline value; where the module is rated on a 1 to 5 scale and refers to hydration level; b) administering a first serving of an oral fluid to the subject; c) repeating the self-rating questionnaire at least 1 time over a 72 hour period after the first serving of the oral fluid is administered; and d) measuring variation in selfrating collected over the c) step period in comparison to the baseline collected in step a).
[0021] Another embodiment of the invention relates to an assessment method of the effectiveness of oral fluid in speed of recovery from acute non-diarrhea illnesses of a subject, the method including: a) submitting the subject to a self-rating questionnaire having at least one module, to create a baseline value; where the module is rated on a 1 to 5 scale and refers to energy level; b) administering a first serving of an oral fluid to the subject; c) repeating the self-rating questionnaire at least 1 time over a 72 hour period after the first serving of the oral fluid is administered; and d) measuring variation in selfrating collected over the c) step period in comparison to the baseline collected in step a).
[0022] A further embodiment of the invention relates to an assessment method of the effectiveness of oral fluid in speed of recovery from acute non-diarrhea illnesses of a subject, the method including: a) submitting the subject to a self-rating questionnaire having at least 2 modules, to create a baseline value, where each module is rated on a 1 to 5 scale and includes a module referring to energy level and a module referring to hydration level; b) administering a first serving of an oral fluid to the subject; c) repeating self-rating questionnaire at least 1 time over a 72-hour period after the first serving of the oral fluid is administered; and d) measuring variation in self rating collected over the c) step period in comparison to the baseline collected in step a).
[0023] By “module” it is meant one or more questions having a particular aspect of the subject physical condition in common. The number of questions in a module is not limited and a module may include one question or more, for example two questions, three questions, four questions; preferably each module includes one question.
[0024] By “oral fluid” it is meant any aqueous solution comprising electrolytes and carbohydrates that may be orally ingested by or administered to a subject, such as ready to drink electrolyte solutions. Electrolytes maybe selected from sodium, potassium, chlorine, citrates, carbonates, bicarbonates, and
combinations thereof. Carbohydrates may be glucose or other mono or disaccharides. Electrolytes are beneficial for hydration and carbohydrates are beneficial for energy restoration. The oral fluid may contain other elements such as magnesium, calcium; or molecules such as taurine or vitamin, for example vitamin C.
[0025] In a preferred embodiment the said oral fluid is a ready to drink electrolyte solutions. In a further preferred embodiment, the said oral fluid is a fruit-based drink with electrolytes.
[0026] The oral fluid may be administered to a subject in need thereof several times a day, for example 1 to 8 times per day, for example 1 to 6 times per day, for example 1 to 4 times per day, for example 2 to 6 times per day, for example 2 to 4 times per day, for example 3 to 6 times per day, for example 3 to 4 times per day; over a period of 24 hours or 48 hours or 72 hours, or over a period as per medical requirement or as medically prescribed. The appropriate number of servings of oral fluid per day, as well as the period over which the servings of the oral fluid should be administrated, to a particular subject is dependent on and defined by the subject’s specific need, based, for example, on medical advice.
[0027] By “serving” of an oral fluid it is meant the volume of oral fluid to be administered to a subject. This volume is subject dependent and is defined as per subject need, based on a medical advice or prescription, given the concentration in electrolytes and carbohydrates of said oral fluid.
[0028] It may be preferable to repeat the self-rating questionnaire several times over the 72 hour period after the first serving of the oral fluid is administered, preferably at least one time, or two times, or even three times during the first 24 hours after the first serving of the oral fluid is administered, for example at 20 minutes, 40 minutes, 60 minutes; and preferably at least one time, or two times, or even three times during the first hour to 72 hour period after the first serving of the oral fluid is administered, for example at 6 hours, 24 hours and 48 hours. Other hour combinations are also possible, including, for example, any combination of 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 56 and 72 hours after the first serving of the oral fluid has been administered.
[0029] Assessments made within the first hour after the first serving of the oral fluid is administered provide information about the onset of response to treatment with the oral fluid, for example the instant energy recovery or the hydration recovery. Assessments made between the first hour and 72 hours after the first serving of the oral fluid first serving administration provide information about the long-lasting response to treatment with the oral fluid, for example the energy recovery or the hydration recovery.
[0030] Examples of “acute non-diarrhea illnesses” may include for example subjects with symptoms such as fever, general weakness, nausea, vomiting; and subjects with conditions like viral illnesses, heat related illness, upper respiratory tract infection (URTI) and urinary tract infections (UTI).
[0031] According to an embodiment, the assessment method may comprise an additional step e) after step d) where step e) is: determining from the measure of step d) the percentage of subject experiencing improvement in one of the energy level module or the hydration level module. By experience an “improvement” in a module it is meant at least a 1 -point increase in rating, compared to the baseline obtained in step a).
[0032] According to a further embodiment, the assessment method may comprise an alternative additional step e’) after step d) where step e’) is: determining from the measure of step d) the percentage of subject experiencing improvement in both the energy level module and the hydration level module.
[0033] It may be beneficial to assess both the hydration and energy levels during recovery at the same time since these two benefits may not be related to the same component of the oral fluid, for example the water and electrolytes component will provide hydration and the carbohydrate component will provide energy. An oral fluid with an insufficient amount of carbohydrate may provide hydration but not sufficient energy recovery.
[0034] According to an embodiment, the assessment method may comprise an alternative additional step e”) after step d) where step e”) is: determining from the measure of step d) the percentage of subject experiencing improvement in the hydration level module.
[0035] The assessment method may exclude questions related to mental health when screening the subject. Eliminating the need to screen subjects for mental health allows the methodology to be simplified for home environment use or any other use that does not require medical supervision. Mental health screening questions, for example those related to depression, are routinely included in medical patient health screening questionnaires.
[0036] The assessment method may also exclude the requirement of any physical test to be performed to screen the subject. Eliminating the requirement for a subject’s physical or medical testing (e.g., urine sample and/or blood work) allows the methodology to be simplified for home environment use or any other use that does not require medical supervision. Furthermore, some physical tests for subjects or patients (e.g., urine color) may be misleading and direct the wrong diagnosis. For example, urine color is darker or lighter depending on the subject and, therefore, is not a reliable indicator of dehydration.
[0037] The assessment method may not need the subject to be in a medical environment, such as a hospital, when the method is performed. It may be beneficial to be able to perform this assessment outside of a medical environment because it allows a subject to evaluate the effectiveness of the oral fluid in naturalistic condition (real life condition) when the subject is at home (in the home environment) or in a remote location. In other words, being able to perform this assessment without any medical environment enables naturalistic, or “in the home environment”, evaluation of the oral fluid without the need of any particular instrument or medical setup. It simplifies the assessment and makes it easier for the subject to comply with the assessment method.
[0038] The assessment method may not need any limitation on the subject’s diet during the method implementation, particularly, no limitation on fluid intake after the first serving of an oral fluid administration of step b). Allowing the subject to keep their regular diet and hydration pattern may be beneficial because it allows naturalistic evaluation of the effectiveness of oral fluid administered. It further provides evidence that the improvement in the subject hydration or energy, or both energy and hydration, is not related to a change in the subject’ s regular diet and hydration pattern but indeed due to
the absorption of the oral fluid. Finally, it does not introduce any burden on the subject in their daily routine, such as the subject’s natural diet and hydration pattern.
[0039] The energy level module may include a question asking the subject to rate his/her level of energy and may provide examples of normal physical activities such as dressing, toileting, eating, bathing, that the subject should be able to perform. Examples like this may help the subject to understand what to focus on. The energy level module may also include other examples of normal physical activities, in addition to or instead of those listed above. Alternatively, the rating and/or question may focus on examples of abnormal physical activities such as fatigue and weakness.
[0040] The hydration level module may include a question asking the subject to rate his/her level of hydration and may provide examples such as having moist tongue/mouth, being able to make saliva or spit, being able to sweat, not feeling thirsty; that the subject should be able to experience when adequately hydrated. Examples like this may help the subject to understand what to focus on. The hydration level module may also include other examples of feeling adequately hydrated, in addition to or instead of those listed above. Alternatively, the rating and/or question may focus on examples of dehydration such as thirst and dry mouth.
[0041] The 1 to 5 scale in the module of the self-rating questionnaire may be associated with indications of which value is the worst and which is the best. For example, the scale may be similar to: 1 = best, 2 = good, 3 = average, 4 = bad, 5 = worst, or conversely 1 = worst, 2 = bad, 3 = average, 4 = good, 5 = best. This indication or a similar indication may enable the subject to avoid any mistake when assessing the effectiveness of the oral fluid. Different subjects, based on their own subjective perception, may consider either 1 or 5 as associated with the best experience. Misinterpretation of the ranking scale may result in subjects providing ranking opposite to their intent. Giving a clear indication of the ranking scale end points relative value helps to avoid any confusion.
[0042] The 1 to 5 scale in the module of the self-rating questionnaire may be associated with a description of physical symptoms for at least part of the values of the scale. For example, the hydration level module could include a scale similar to the following: 1 = not thirsty, 2 = slightly thirsty, 3 = thirsty, 4 = very thirsty and 5 = extremely thirsty. This indication or a similar indication may enable the subject to avoid any mistake when assessing the effectiveness of the oral fluid. Different subjects, based on their own subjective perception, may consider cither 1 or 5 as associated with the best experience. Misinterpretation of the ranking scale may result in subjects providing ranking opposite to their intent. Giving a clear indication of the ranking scale end points relative value helps to avoid any confusion.
[0043] According to an embodiment, the assessment method may be implemented by software or a software App on a mobile device such as a smartphone. Implementation of the assessment method on a smartphone may make it easier to use and/or more convenient for the subject and/or medical professional using the App. It would allow the assessment method to be used outside medical facilities and/or the home environment. Having data directly in a digital format also allows reduction of paperwork and potential transcription mistakes.
[0044] The assessment method may be implemented by a software App on a mobile device, where the App may be programmed to make a recommendation for the purchase of oral fluid, such as a ready to drink electrolyte solutions or fruit-based drink with electrolytes. The recommendation may be made by an algorithm that evaluates the subject’s answers to the self-rating questionnaire. The recommendation could also be made by a medical professional that is affiliated with the App, for example a virtual doctor or nurse.
[0045] The software App may be further able to link a recommendation to a third-party website selling the recommended oral fluid or may have a direct-to-consumer purchase platform for the recommended oral fluid, so that the subject can immediately purchase the oral fluid for treatment. Having an automatic recommendation of an appropriate oral fluid with electrolytes and carbohydrates, such as a ready to drink electrolyte solution, may help the subject to get quick access to the relevant product to address the lack of hydration and/or energy. Or, if the App were used by a medical professional, rather than by the subject or patient, it may also help the medical staff to make recommendation of products adapted to the subject needs.
Examples
[0046] Study Design: To study the effect of oral fluid in dehydration and energy recovery in subjects, using the above referenced assessment methodology the following prospective, interventional, open-label, multicenter, naturalistic study involving subjects was conducted. Subjects were supplied with an oral fluid, in particular with one of the ORSL® variants (ORSL® Apple Drink or ORSL® PLUS Orange Drink), as an adjuvant along with standard of care medication treatment, as per physician’ s discretion in subjects experiencing acute common non-diarrheal illnesses with fever and/or general weakness, e.g. upper respiratory tract infection (URTI). Hydration and energy levels were evaluated following consumption of ORSL® variant through an assessment methodology, referred to as the “Aided Recovery Scale Questionnaire” (collected by patient-reported outcome (PRO)) followed by telephone interview or online review with the physician. The data were recorded in this study both by subjects via a “Aided Recovery Scale” and a “Subject Experience Questionnaire” and by physicians via a “Physician Recommendation Experience questionnaire”. The study was conducted over a period of 72 hours (and up to 78 hours in case follow-up of an adverse event [AE] was required). The term “patient” in this example of study is equivalent to the term “subject” in the rest of the specification.
[0047] Subjects who presented to a hospital, out-patients department (OPD) or clinic with fever and/or general weakness due to an acute non-diarrheal illness such as URTI were examined by a physician. When the clinical decision was taken to recommend ORSL® variants as an adjuvant to a subject, the physician considered enrolling the subject into this study. During the in-clinic visit, after signing the informed consent form (ICF) and enrollment into the study, subjects were trained and instructed on the use of diary cards. The subjects were also trained on using Subject Experience questionnaire which were
completed after telephone interview or online. The subjects were provided with ORSL® variant packs as recommended by the physician sufficient for the duration of the study. The subject left the site/study center, and ORSL® variant packs consumption and all assessments were conducted at the subject’s home.
[0048] The subjects recorded their experiences in their energy and hydration level using the “Aided Recovery Scale” starting from baseline (prior to consumption of ORSL® variant) and at 20, 40 and 60 minutes, 6, 24 and 48 hours after consumption. On completion, the Aided Recovery Scale Questionnaire from each patient was securely transferred to sponsor. Each subject visited the study site on one occasion for inclusion into the study. A follow-up call by the Investigator to the subject took place after 72 hours. No further in-clinic visits were in the scope of this study, unless deemed necessary by the Investigator.
[0049] Study Population: Patient inclusion criteria included subjects greater or equal to 18 years of age, who:
• were able to comprehend and willing to sign an Informed consent form (ICF) and to comply with all aspects of the Study;
• were willing and able to respond to subjective questions;
• had a score of 3 or greater in both energy and hydration on the “Aided Recovery Scale” at the time of the screening (baseline) visit; and
• were diagnosed in the preceding two weeks with acute febrile illness (e.g. URTI, viral illness) and/or generalized weakness/fatigue due to acute non-diarrheal illness.
[0050] Exclusion Criteria: Patients were excluded for the following reasons:
• Subjects needing in-patient hospitalization
• Subjects who had undergone any GI surgeries, which are known to affect absorption anytime in the past
• Women who had a positive pregnancy test at screening
• Subjects with pre-existing medical conditions that may have impacted study measurements or ability to comply with study procedures, including but not limited to malabsorption syndrome, congestive heart failure, cirrhosis, hepatic failure, malignancy, sepsis, chronic infections like Tuberculosis, Chronic obstructive pulmonary disease, Syndrome of inappropriate antidiuretic hormone secretion, renal failure, etc.
• Participation in any clinical trials in the last 3 months
• Use of any other oral rehydration solution and/or any other ready to drink solution in the last 48 hours.
• Use of any medications which might have interacted with oral rehydration solution as per physician discretion
• Subjects with nausea, vomiting, diarrhea, suspected or confirmed malaria, dengue or typhoid confirmed by culture positive test, active CO VID- 19 disease, subjects in convalescence post COVID-19 <3 weeks and off steroids <2 weeks
• Subjects presenting with a urinary tract infection (UTI)
• Subjects who, in the Investigator’s opinion, were not suitable to take part in the study
• Subjects who were related to those persons involved directly or indirectly with the conduct of this study (i.e., Principal Investigator, sub-investigators, study coordinators, other site personnel, employees of the applicant company, contractors of the applicant company, and the families of each)
[0051] Discontinuation Criteria: Subjects who developed diarrhea, or were diagnosed with malaria, culturepositive typhoid, dengue, CO VID-19 (newly diagnosed), etc. or required hospitalisation for any cause were discontinued from the study. However, data collected for such subjects were retained for the purpose of analysis and no further efforts were made to obtain or record additional information regarding the subject from the point of discontinuation.
[0052] Data Collection/Data Sources: The data for the study was collected at relevant data timepoints as presented in the data collection schedule. At baseline, the treating physician carried out a physical examination and recorded demographics, medical history, details of primary ailment) s) and the standard of care medication treatment and their concomitant medications (including nutritional supplements). The data for effectiveness evaluation was recorded by subjects on PRO questionnaires in the home environment. Physicians recorded the 72-hour evaluation on the Physician Recommendation experience questionnaire. For safety evaluation, adverse event (AEs) and serious adverse events (SAEs) were recorded starting from the time of signing of the ICF. The staff from individual sites entered the study data in the electronic case report forms (eCRFs) of the Electronic data capture (EDC) system.
[0053] Data Management and Quality Assurance: The CRFs included programming checks to obtain immediate feedback if data were missing, out of range, illogical or potentially erroneous. Concurrent manual data review was performed based on parameters dictated by the data management plan.
[0054] Effectiveness: The effectiveness of the study was evaluated by comparison of:
• Patient reported outcome - Aided Recovery Scale questionnaire and Subject Experience Questionnaire; and
• Physician reported outcome: Physician Recommendation Experience Questionnaire
[0055] Statistical Considerations: Regarding sample size, a sufficient number of subjects (617) who met the required inclusion/exclusion criteria were enrolled to ensure that 524 subjects completed the study, considering a drop-out rate of approximately 15%.
[0056] Final Analyses: Summary statistics were presented overall and by variant at baseline and post-baseline visits. Baseline and demographic characteristics were presented overall and by variant. Statistical tests for primary and secondary endpoints were based on hypothesis. A one sample binomial test with normal approximation was used to test whether the proportion improved significantly differs from 50%.
[0057] Thinking of the potential ability to pass along unused alpha to secondary endpoints, and the uncertainty of timely sequential performance, the truncated Holm multiple comparison procedure was applied in order to strongly control the family wise Type I error rate at 0.025, one-sided, for the different timepoints involved in each kind of primary endpoints and secondary effectiveness endpoints.
[0058] The truncated Holm multiple comparison procedure (a hybrid of its conventional form and the Bonferroni method) with a truncation fraction, 1/2, was applied. The three primary endpoints (at 6 hours, 24 hours and 48 hours) were categorized into the primary family, and the other 3 timepoints (at 20 mins, 40 mins and 60 mins) were categorized into the secondary family.
[0059] The number and percentage of subjects experiencing adverse events, treatment-emergent and treatment- related AEs during the clinical study were presented by Medical Dictionary for Regulatory Activities, System Organ Class preferred term and variant.
[0060] Exposure Definition and Measures: This was a naturalistic interventional study reflecting current clinical practice. This study evaluated effectiveness, and physician and subjects’ responses to investigational product (IP) measured in the post-marketing setting. No restrictions on concomitant treatments were associated with the study and all concomitant treatments were carefully recorded in order to evaluate their potential influence on the outcomes of interest.
[0061] End of Study Definition: The study was conducted over a period of 72 hours for each subject (and up to 78 hours in case follow-up of an AE was required).
[0062] Provision of Investigational Product: The Sponsor, Johnson & Johnson, Consumer Healthcare supplied the Investigational Products (ORSL® variant packs) and the subjects received these packs required for 72 hours from the study sites.
• ORSL® Apple Drink is a fruit juice -based drink with electrolytes (sodium, potassium and chloride), vitamin C and carbohydrates in a 200 mL pack. It is presented in a tetrabrik aseptic package.
• ORSL® PLUS Orange Drink is a fruit juice-based drink with electrolytes (sodium, potassium and chloride), vitamin C and carbohydrates in a 200 mL pack. It is presented in a tetrabrik aseptic package.
[0063] ORSL® Apple Drink and ORSL® PLUS Orange Drink are Food products classified as “Electrolyte Drink”, not ORS, under applicable regulations laid down by Food Standard and Safety Authority of India. Exemplary ingredient and nutritional information of the ORSL® Apple Drink and ORSL® PLUS Orange Drink are provided below:
[0064] ORSL® Apple Drink (Figure 1):
Net Quantity: 200ml (1 serve of 200ml)
Ingredients:
Purified Water, Sugar, Dextrose, Apple Juice (reconstituted) 10%, Acidity Regulator (INS330), Sodium Citrate, Potassium chloride, Sodium chloride, Vitamin C (Ascorbic acid), Added Flavours (Nature Identical Flavoring Substances & Artificial Flavouring Substances [Apple]).
* Basis RDA for Adult Sedentary male, ICMR, 2020
[0065] ORSL® PLUS Orange Drink (Figure 2):
Net Quantity: 200ml (1 serve of 200ml)
Ingredients:
Water, Sugar, Dextrose, Orange Juice (reconstituted) 10%, Sodium Citrate, Acidity Regulator (INS330), Potassium chloride, Sodium chloride, Vitamin C (Ascorbic acid), Taurine, Magnesium sulphate, Calcium lactate, Added Flavours (Nature Identical Substances [Orange], Antioxidant (INS 320)).
* Basis RDA for Adult Sedentary male, ICMR, 2020
[0066] Compliance With Investigational Product Usage: The subjects recorded the time and number of packs of their ORSL® variant consumed on diary cards.
[0067] Effectiveness Measures: Aided Recovery Scale Questionnaire consisted of 2 questions i.e., “Rate your level of energy” and “Rate your level of hydration”, which corresponded to 2 primary objectives of the study. Subjects provided their response to these questions on a scale from 1 to 5 after self-assessment of their condition of illness and how much they feel recovered after taking ORSL® variant. The responses were as follows: Strongly Disagree-1 to Strongly Agree-5. Further details on these 2 questions are provided in table below.
An exemplary Aided Recovery Scale Questionnaire may be as follows:
[0068] As can be seen the Aided Recovery Scale questionnaire comprises two modules, one relating to energy: “Rate your level of energy”; and one related to hydration: “Rate your level of hydration”. Both provide examples of physical activities that the patient should be able to perform or experience when having an adequate level of energy or being adequately hydrated. These examples are provided to help the patient in the self-rating.
[0069] Screening (Baseline): Subjects were included in the study and were screened for inclusion and exclusion criteria after they or their legal representative agreed to participate in the study and signed the ICF. The subjects meeting all the eligibility criteria were enrolled in the study. The enrolled subject’s baseline data was collected by the treating physician (or designee) before administering first usage of any of the ORSL® variants.
[0070] Subjects were enrolled into the study not beyond 6:00 PM in the evening as it may have been difficult to collect data from subjects if they were enrolled after this time. The participants were provided with proper training on completing the diary cards.
[0071] Assessments (20 [± 51, 40 [± 51 and 60 [± 51 minutes): After the first consumption (after enrolment into the study) of ORSL® variants by subjects at home, subjects were responsible for recording their experience in energy levels and hydration with ORSL® variants at 20 (± 5), 40 (± 5), and 60 (± 5) minutes via “Aided Recovery Scale” questionnaire.
[0072] Assessments (6 [± 1] hours, 24 [± 4] hours, 48 [+ 4] hours and 72 [+ 4] hours): After leaving the site, the subjects consumed IPs at home, recorded the time and volume of their ORSL® variant intake (number of ORSL® variant packs used) and any AEs experienced by them on the diary cards. Subject’s experience in their energy level and hydration status at 6 (+ 1) hours, 24 (± 4) hours and 48 (± 4) hours
after consumption of ORSL® variants administration were recorded by the subject themselves using “Aided Recovery Scale” questionnaire. No further site visit was required as part of this study. A telephone interview/online review by a designated study site personnel at 72 (± 4) hours was conducted for understanding the subject’s overall experience with ORSL® variant via Subject Experience questionnaire.
[0073] At 72 (± 4) hours after ORSL® variant intake, the physician contacted the subject to perform a telephone interview to assess the condition of the subject. The physician completed the assessment questionnaire. The site staff entered the data in the eCRF. At 24 (± 4) hours, 48 (± 4) hours and 72 (± 4) hours, fluids consumed in addition to ORSL® variant were also recorded to the best of subject’s memory.
[0074] Results: 617 subjects were enrolled in the study. 310 subjects received the ORSL Apple variant, and 307 subjects received the ORSL Orange Variant. All subjects completed the study, no discontinuation was observed. 62.4% of subjects were male and 37.6% of the subjects were female. The median age was 36 years (minimum 18 years, maximum 79 years). The mean age was 38.3 years with a standard deviation of 12.85. The baseline BMI (kg/m2) had a mean value of 23.85 (Std Dev 3.127), and a median value of 23.60.
[0075] Assessment based on energy or hydration: Table 1 shows the percentage of subjects feeling an improvement in either energy or hydration on “Aided Recovery Scale” after 6, 24 and 48 hours of ORSL® variants consumption. By “improvement” is meant at least 1 point improvement from baseline.
[0076] Assessment based on energy alone: Table 2 shows the percentage of subject feeling an improvement in energy on “Aided Recovery Scale” after 6, 24 and 48hours of ORSL® variants consumption. By “improvement” is meant at least 1 point improvement from baseline.
Table 2
[0077] Assessment based on hydration alone: Table 3 shows the percentage of subjects feeling an improvement in hydration on “Aided Recovery Scale” after 6, 24 and 48hours of ORSL® variants consumption. By “improvement” is meant at least 1 point improvement from baseline.
[0078] Assessment based on energy and hydration: Table 4 shows the percentage of subject feeling an improvement in both energy and hydration on “Aided Recovery Scale” after 6, 24 and 48hours of ORSL® variants consumption. By “improvement” is meant at least 1 point improvement from baseline.
[1] Binomial test with normal approximation was used to test whether the proportion improved was significantly greater than 50%.
[0080] Percentage improved was statistically significantly greater than 50%. The truncated Holm multiple comparison procedure was applied in order to strongly control the family wise Type I error rate at 0.025, one-sided.
[0081] From the results presented in tables 1 to 4 about assessing hydration and energy level, it can be concluded that the subjects experienced an improvement in their hydration or energy level or both hydration and energy level. This beneficial effect started to be observed within one hour of administration of the oral fluid to the subjects and was observed in 98% or more of the subjects at 48 hours. Implementation of this method in a smartphone application would show the subject that the oral fluid is working.
[0082] The assessment methodology demonstrates the ability to detect low levels of hydration and/or energy and assess improvement in hydration and energy levels in subjects over time after administration of oral fluids.
[0083] It is understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims.
Claims
Claims
1) A method to assess an effectiveness of an oral fluid in a treatment of a subject suffering from an acute non-diarrhca illness, the method comprising: a) having the subject answer a self-rating questionnaire comprising a module related to hydration level, wherein the subject selects a self-rating based on a 1 to 5 scale to create a baseline value; b) administering a first serving of the oral fluid to the subject; c) having the subject repeat the self-rating questionnaire at least one time over a 72-hour period after the first serving of the oral fluid is administered to create at least one additional value; and d) measuring a variation between the at least one additional value collected in step c) and the baseline value collected in step a), wherein the variation indicates the effectiveness of the oral fluid in the treatment of the subject.
2) A method to assess an effectiveness of an oral fluid in a treatment of a subject suffering from an acute non-diarrhea illness, the method comprising: a) having the subject answer a self-rating questionnaire comprising a first module and a second module, wherein the first module relates to energy level and the second module relates to hydration level, and wherein the subject selects a self-rating on a 1 to 5 scale to create a baseline value for each of the first module and the second module; b) administering a first serving of the oral fluid to the subject; c) having the subject repeat the self-rating questionnaire at least one time over a 72-hour period after the first serving of the oral fluid is administered to create at least one additional value for each of the first module and the second module; and d) measuring a variation between the at least one additional value collected in step c) and the baseline value collected in step a) for each of the first module and the second module, wherein the variation indicates the effectiveness of the oral fluid in the treatment of the subject.
3) The method according to claim 1 or 2, wherein step c) comprises having the subject repeat the selfrating questionnaire at least one time during the first 24 hours after the first serving of the oral fluid is administered.
4) The method according to claim 1 or 2, wherein step c) comprises having the subject repeat the selfrating questionnaire at least one time during a period between 1 hour and 72 hours after the first serving of the oral fluid is administered.
5) The method according to claim 1 or 2, wherein step c) comprises having the subject repeat the selfrating questionnaire at least one time during the first 24 hours after the first serving of the oral fluid is
administered, and having the subject repeat the self-rating questionnaire at least one additional time during a period between 1 hour and 72 hours after the first serving of the oral fluid is administered.
6) The method according to any of claims 2 to 5, further comprising: e) determining from the variation of step d) whether the subject experienced an improvement in one of the first module or the second module.
7) The method according to any of claims 2 to 5, further comprising: e’) determining from the variation of step d) whether the subject experienced an improvement in both the first module and the second module.
8) The method according to any of claims 2 to 5, further comprising: e’ ’) determining from the variation of step d) whether the subject experienced an improvement in the second module.
9) The method of claim 1, further comprising: e) determining from the variation of step d) whether the subject experienced an improvement in the module.
10) The method according to any of the preceding claims, wherein said oral fluid is a ready to drink electrolyte solution.
11) The method according to any of the preceding claims, wherein the subject does not need to be in a medical environment, such as a hospital, when the method is performed.
12) The method according to any of the preceding claims, wherein the subject has no limitation on diet during the method, particularly, no limitation on fluid intake after the first serving of the oral fluid is administered in step b).
13) The method according to claim 2, wherein the first module comprises a question asking the subject to rate his/her level of energy and further comprises examples of normal physical activities such as dressing, toileting, eating, bathing, that the subject should be able to perform when adequately energized.
14) The method according to claim 2, wherein the second module comprises a question asking the patient to rate his/her level of hydration and further comprises examples such as having moist tongue/mouth, being able to make saliva or spit, being able to sweat, not feeling thirsty, that the patient should be able to experience when adequately hydrated.
15) The method according to any of the preceding claims, wherein the 1 to 5 scale further comprises a description of physical symptoms associated with each value of the 1 to 5 scale.
16) The method according to any of the preceding claims, wherein the method is implemented by a software on a mobile device such as a smartphone.
17) The method of claim 16, wherein the software uses the baseline value collected in step a) to recommend a type or amount of oral fluid to be administered to the subject in step b).
18) The method of claim 17, wherein the software further enables the purchase of the type of oral fluid to be administered to the subject in step b).
19) The method of claim 16, wherein the software uses the variation measured in step d) to determine whether the subject experienced an improvement in the module or whether additional treatment may be necessary.
20) The method of claim 16, wherein the software may be used by the subject or a medical professional.
21) The method according to any of the preceding claims, wherein the method is adapted to assess an effectiveness of an oral fluid in the treatment of multiple subjects suffering from the same or various acute non-diarrhea illnesses.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202211032278 | 2022-06-06 | ||
IN202211032278 | 2022-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023239684A1 true WO2023239684A1 (en) | 2023-12-14 |
Family
ID=87036109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/024513 WO2023239684A1 (en) | 2022-06-06 | 2023-06-06 | Methodology related to dehydration treatment |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023239684A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090148566A1 (en) * | 2003-11-12 | 2009-06-11 | Stokely-Van Camp, Inc. | Carbohydrate And Electrolyte Replacement Composition |
US20170228517A1 (en) * | 2016-02-08 | 2017-08-10 | OutcomeMD, Inc. | Systems and methods for determining a wellness score, an improvement score, and/or an effectiveness score with regard to a medical condition and/or treatment |
CN109961330A (en) * | 2017-12-14 | 2019-07-02 | 深圳卓和云投资控股有限公司 | A kind of beverage recommended method and intelligent beverage drinker |
WO2021240827A1 (en) * | 2020-05-29 | 2021-12-02 | パナソニックIpマネジメント株式会社 | Control method, communication terminal, program, storage medium, and information provision method |
-
2023
- 2023-06-06 WO PCT/US2023/024513 patent/WO2023239684A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090148566A1 (en) * | 2003-11-12 | 2009-06-11 | Stokely-Van Camp, Inc. | Carbohydrate And Electrolyte Replacement Composition |
US20170228517A1 (en) * | 2016-02-08 | 2017-08-10 | OutcomeMD, Inc. | Systems and methods for determining a wellness score, an improvement score, and/or an effectiveness score with regard to a medical condition and/or treatment |
CN109961330A (en) * | 2017-12-14 | 2019-07-02 | 深圳卓和云投资控股有限公司 | A kind of beverage recommended method and intelligent beverage drinker |
WO2021240827A1 (en) * | 2020-05-29 | 2021-12-02 | パナソニックIpマネジメント株式会社 | Control method, communication terminal, program, storage medium, and information provision method |
US20230062061A1 (en) * | 2020-05-29 | 2023-03-02 | Panasonic Intellectual Property Management Co., Ltd. | Control method, communication terminal, non-transitory computer-readable recording medium, and information providing method |
Non-Patent Citations (1)
Title |
---|
DAVID JIM?NEZ-PAV?N ET AL: "Effects of a moderate intake of beer on markers of hydration after exercise in the heat: a crossover study", JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION, BIOMED CENTRAL LTD, LO, vol. 12, no. 1, 6 June 2015 (2015-06-06), pages 26, XP021224150, ISSN: 1550-2783, DOI: 10.1186/S12970-015-0088-5 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Prakash et al. | Prevalence of early childhood caries and associated risk factors in preschool children of urban Bangalore, India: A cross-sectional study | |
Couzos et al. | National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people | |
Chessa et al. | What do parents know about the malformations afflicting the hearts of their children? | |
Wagner et al. | Dietary Intervention for Glucose Tolerance In Teens (DIG IT): Protocol of a randomized controlled trial using health coaching to prevent youth-onset type 2 diabetes | |
WO2023239684A1 (en) | Methodology related to dehydration treatment | |
Stillman | The incidence of pica in a sample of dialysis patients | |
Yan et al. | The effects of collaborative care model (CCM) guided nursing practice on the self-management and self-efficacy of kidney transplant recipients | |
Baer | A guide to living with thalassemia | |
Singh et al. | Effectiveness of an Educational Intervention via Health Belief Model in Promoting Self Care Behavior in Type II Diabetes Mellitus Patients in Lucknow Province of Uttar Pradesh, India: Randomized Controlled Trial | |
Abdulnabi et al. | Assessment of Parents' Performance about Nutritional Management of Children with Phenylketonuria | |
Duggan et al. | Survey of Nutrition Education Among Medical Students | |
Chaffee et al. | Measuring health from the inside: Nutrition, metabolism & body composition | |
GUPTA et al. | Self-care Behaviour of Pregnant Women with Gestational Diabetes Mellitus at a Tertiary Care Hospital in Lucknow, India: A Quasi-experimental Study. | |
Cooper et al. | Study Guide for Adult Health Nursing-E-Book | |
Kagasi | Nutritional Status and Prevalence of Dental Caries among Children aged 3-5 Years attending Outpatients Health Care at Gertrude’s Children’s Hospital in Nairobi, Kenya (2011-2012) | |
Moffit | Page BASELINE PREDICTORS OF PROGRAM ENGAGEMENT IN AN ONLINE PHYSICAL ACTIVITY INTERVENTION | |
Lawrence | Dental caries, tooth wear and dietary sugar intake in a sample of Northland Māori. | |
Dysphagia | European Society for Swallowing Disorders | |
Khalili | Effect of a confined program of home-care on the health status of patients recieving hemodialysis | |
Sabbahi | The Effectiveness of Oral Health Education Among Non-dental Healthcare Professionals in Jeddah, Saudi Arabia: A Quasi-experimental Study | |
Murillo et al. | Hospital management of the patient with dysphagia. Survey and recommendations of SEEN nutrition area | |
Jernigan | Acceptability and Feasibility of a Dietary and Exercise Intervention Delivered via Telehealth Emphasizing the DASH Diet and High Intensity Interval Training for Adolescents with Elevated Weight Status: The DASH-IT Pilot Study | |
Rosário et al. | Adipocytokines and attained height in adolescence: a longitudinal analysis | |
Rêgo et al. | 28th Annual Congress of European Childhood Obesity Group (ECOG) Porto, November 14–17, 2018 | |
Agostinis-Sobrinho et al. | Adiponectin status in different metabolic phenotypes on insulin resistance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23734848 Country of ref document: EP Kind code of ref document: A1 |